Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer

Chemotherapy

Volumn 52, Issue 6, 2006, Pages 301-307

  Ishizone, Satoshi ^a   Maruta, Fukuto ^a   Saito, Hiroyasu ^a   Koide, Naohiko ^a   Sugiyama, Atsushi ^a   Nakayama, Jun ^a   Miyagawa, Shinichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer, gastric; Metastasis, peritoneal; S 1; Thymidine, phosphorylase

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DIHYDROPYRIMIDINE DEHYDROGENASE; MESSENGER RNA; OROTATE PHOSPHORIBOSYLTRANSFERASE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; EYE TOXICITY; FEMALE; GASTRECTOMY; GENE EXPRESSION; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA; PERITONEUM METASTASIS; PRIORITY JOURNAL; SKIN MANIFESTATION; STOMACH CANCER; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG COMBINATIONS; FEMALE; GASTRECTOMY; HUMANS; INTESTINAL NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXONIC ACID; PATIENT COMPLIANCE; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33750242993     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096002     Document Type: Article

References (32)

1. Sakakura C, Hagiwara A, Nakanishi M, Shimomura K, Takagi T, Yasuoka R, Fujita Y, Abe T, Ichikawa Y, Takahashi S, Ishikawa T, Nishizuka I, Morita T, Shimada H, Okazaki Y, Hayashizaki Y, Yamagishi H: Differential gene expression profiles of gastric cancer cells established from primary tumour and malignant ascites. Br J Cancer 2002;87:1153-1161.
2. Kodera Y, Nakanishi H, Yamamura Y, Shimizu Y, Torii A, Hirai T, Yasui K, Morimoto T, Kato T, Kito T, Tatematsu M: Prognostic value and clinical implications of disseminated cancer cells in the peritoneal cavity detected by reverse transcriptase-polymerase chain reaction and cytology. Int J Cancer 1998;79:429-433.
3. Ikeguchi M, Matsumoto S, Yoshida S, Murakami D, Kanaji S, Ohro S, Yamaguchi K, Saito H, Tanabe S, Kondo A, Tsujitani S, Kajbara N: Laparoscopic-assisted intraperitoneal chemotherapy for patients with scirrhous gastric cancer. Chemotherapy 2005;51:15-20.
4. Kitamura Y, Hayashi K, Sasagawa T, Oguma H, Takasaki K: Pilot study of S-1 in patients with disseminated gastric cancer. Drugs Exp Clin Res 2003;29:125-130.
5. Osugi H, Takada N, Takemura M, Kaseno S, Lee S, Ueno M, Tanaka Y, Fukuhara K, Fujiwara Y, Kinoshita H: Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination. Oncol Rep 2002;9:811-815.
6. Fujitani K, Tsujinaka T, Hirano M: Feasibility study of S-1 for resectable gastric cancer with peritoneal seeding. Hepatogastroenterology 2003;50:889-892.
7. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-557.
8. Shirasaka T, Shimamoto Y, Fukushima Y: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53: 4004-4009.
9. Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T,. Takechi T: Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 1998;13:693-698.
10. Kato T, Shimamoto Y, Uchida J, Ohshimo H, Abe M, Shirasaka T: Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulations consisting of S-1, a new oral formulation of 5-fluorouracil. Anticancer Res 2001;21:1705-1712.
11. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydropyrimidine-1M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted in nude rat. Cancer Res 1996;56:2602-2606.
12. Aschele C, Lonardi S, Monfardini S: Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 2002;28:27-47.
13. Terashima M, Irinoda T, Fujiwara H, Nakaya T, Takagane A, Abe K, Yonezawa H, Oyama K, Inaba T, Saito K, Takechi T, Fukushima M: Roles of thymidylate synthase and dipyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res 2002;22:761-768.
14. Fujiwara H, Terashima M, Irinoda T, Takagane A, Abe K, Kashiwaba M, Oyama K, Takahashi M, Waesawa C, Saito K, Takechi T, Fukushima M: Quantitative measurement of thymidylate synthase and dipyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR. Jpn J Cancer Res 2002;93:1342-1350.
15. Isshi K, Sakuyama T, Gen T, Nakamura Y, Kuroda T, Katuyama T, Maekawa Y: Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol 2002;7:335-342.
16. Hirano Y, Kageyama S, Ushiyama T, Suzuki K, Fujita K: Clinical significance of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in transitional cell cancer. Cancer Chemother Pharmacol 2003;51:29-35.
17. Inada M, Mitsuhashi J, Sawada H, Miike N, Naoe Y, Daimen A, Koizumi K, Tsujimoto H, Fukushima M: Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res 1996;87:212-220.
18. Miyadera K, Sunizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y: Role of thymidine phosphorylase activity in the angiogenesis effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 1995;55:1687-1690.
19. NCI Common Toxicity Criteria. Bethesda, National Cancer Institute, Division of Cancer Treatment, 1988.
20. Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, Bremner CG, Tsai PI, Danenberg PV: Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia. adenocarcinoma sequence. J Gastrointest Surg 2000;4:135-142.
21. Farrugia DC, Ford HE, Cunningham D, Danenberg KD, Danenberg PV, Brabender J, McVicar AD, Aherne GW, Hardcastle A, McCarthy K, Jackman AL: Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin Cancer Res 2003;9:792-801.
22. Ichikawa W, Takahashi T, Suto K, Nihei Z, Shirota Y, Shimizu M, Sasaki Y, Hirayama R: Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer. Int J Cancer 2004;112:967-973.
23. Kornmann M, Schwabe W, Sander S, Kron M, Strater J, Polat S, Kettner E, Weiser HF, Baumann W, Schramm H, Hausler P, Ott K, Behnke D, Staib L, Beger HG, Link KH: Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003;9:4116-4124.
24. Ichikawa W, Takahashi T, Suto K, Yamashita T, Nihei Z, Shirota Y, Shimizu M, Sasaki Y, Hirayama R: Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 2004;91:1245-1250.
25. Funato T, Kozawa K, Fujimaki S, Miura T, Kaku M: Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the her-2/neu (c-erbB-2) gene. Chemotherapy 2001;47:297-303.
26. Matthew H, Kulke MD: The treatment of advanced gastric cancer: in search of the right combination. J Clin Oncol 2000;18:2645-2647.
27. Tahara M, Ohtsu A, Boku N, Nagashima F, Muto M, Sano Y, Yoshida M, Mera K, Hironaka S, Tajiri H, Yoshida S: Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study. Gastric Cancer 2001;4:212-218.
28. Sabri B, Ceyhun C, Nezih M, Banu O, Tarkan T, Alper O, Gurhan K, Zahit B: A new perspective on cardiotoxicity of 5-fluorouracil. Chemotherapy 2004;50:113-118.
29. Kakeji Y, Maehara Y, Shibahara K, Hasuda S, Oshiro T, Bata H: Heterogeneity and clinical role of thymidine phosphorylase activity in gastric cancer. Oncol Rep 1999;6:1213-1216.
30. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M: Thymidine phosphorylase/platelet-derived endothelial cell factor expression associated with hepatic metastasis in gastric carcinoma. Br J Cancer 1996;73:884-888.
31. Cook AF, Holman MJ, Kramer MJ, Trown PW: Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5′-deoxy-5-fluoropyrimidine nucleosides. J Med Chem 1979;22:1330-1335.
32. Ichikawa W, Takahashi T, Suto K, Hirayama R: Gene expressions for thymidylate synthase (TS), orotate phosphoribosyltransferase (OPRT), and thymidine phosphorylase (TP), not dihydropyrimidine dehydrogenase (DPD), influence outcome of patients (pts) treated with S-1 for gastric cancer (GC). ASCO proceedings. J Clin Oncol 2004;22:4050.